Header Logo

Connection

SETH LERNER to Humans

Back to Details
This is a "connection" page, showing publications SETH LERNER has written about Humans.
SETH LERNER
Connection Strength
1.240
Humans
  1. Association of Molecular Subtypes with Pathologic Response, PFS, and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. Clin Cancer Res. 2024 01 17; 30(2):444-449.
    View in: PubMed
    Score: 0.019
  2. Phase 2 Trial of Atezolizumab in Bacillus Calmette-Gu?rin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605. Eur Urol. 2023 12; 84(6):536-544.
    View in: PubMed
    Score: 0.018
  3. Poly (ADP-ribose) Polymerase Inhibition in Advanced Urothelial Carcinoma. JCO Precis Oncol. 2023 08; 7:e2300293.
    View in: PubMed
    Score: 0.018
  4. Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695). Eur Urol. 2023 09; 84(3):341-347.
    View in: PubMed
    Score: 0.018
  5. Evolving the surgical approach for bladder cancer - robotic versus open radical cystectomy. Nat Rev Urol. 2023 04; 20(4):203-204.
    View in: PubMed
    Score: 0.018
  6. Risk Stratification of Nonmuscle Invasive Bladder Cancer and Innovative Approaches to Management of Ta Low-Grade Tumors. J Clin Oncol. 2023 01 10; 41(2):163-166.
    View in: PubMed
    Score: 0.017
  7. Drug instillation in the management of urinary tract urothelial carcinoma. Curr Opin Urol. 2022 09 01; 32(5):531-535.
    View in: PubMed
    Score: 0.017
  8. Durability of Response to Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101, a Mitomycin-Containing Reverse Thermal Gel: OLYMPUS Trial Final Report. J Urol. 2022 Apr; 207(4):779-788.
    View in: PubMed
    Score: 0.016
  9. Re: Identification of Differential Tumor Subtypes of T1 Bladder Cancer. Eur Urol. 2022 01; 81(1):118-119.
    View in: PubMed
    Score: 0.016
  10. Phase II multi-center trial of optical coherence tomography as an adjunct to white light cystoscopy for intravesical real time imaging and staging of bladder cancer. Urol Oncol. 2021 07; 39(7):434.e23-434.e29.
    View in: PubMed
    Score: 0.016
  11. Novel Thermo-Sensitive Hydrogel Therapy for Low-Grade Upper Tract Urothelial Carcinoma. J Urol. 2021 08; 206(2):191-193.
    View in: PubMed
    Score: 0.016
  12. Pharmacokinetics of UGN-101, a mitomycin-containing reverse thermal gel instilled via retrograde catheter for the treatment of low-grade upper tract urothelial carcinoma. Cancer Chemother Pharmacol. 2021 06; 87(6):799-805.
    View in: PubMed
    Score: 0.015
  13. Targeting barriers to wider use of trimodality therapy in localized muscle invasive bladder cancer. Urol Oncol. 2023 01; 41(1):35-38.
    View in: PubMed
    Score: 0.015
  14. Utility of lymphadenectomy in bladder cancer: where do we stand? Curr Opin Urol. 2020 05; 30(3):407-414.
    View in: PubMed
    Score: 0.015
  15. Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial. Lancet Oncol. 2020 06; 21(6):776-785.
    View in: PubMed
    Score: 0.015
  16. The Cancer Genome Atlas Expression Subtypes Stratify Response to Checkpoint Inhibition in Advanced Urothelial Cancer and Identify a Subset of Patients with High Survival Probability. Eur Urol. 2019 06; 75(6):961-964.
    View in: PubMed
    Score: 0.013
  17. What is the Standard of Care for Pelvic Lymphadenectomy Performed at the Time of Radical Cystectomy? Eur Urol. 2019 04; 75(4):612-614.
    View in: PubMed
    Score: 0.013
  18. SIU-ICUD consultation on bladder cancer: basic science. World J Urol. 2019 Jan; 37(1):15-29.
    View in: PubMed
    Score: 0.013
  19. Background and Update for S1602 "A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-na?ve High-grade Non-muscle-invasive Bladder Cancer. Eur Urol Focus. 2018 07; 4(4):522-524.
    View in: PubMed
    Score: 0.013
  20. The Cancer Genome Atlas Project in Bladder Cancer. Cancer Treat Res. 2018; 175:259-271.
    View in: PubMed
    Score: 0.012
  21. Molecular Landscape of Non-Muscle Invasive Bladder Cancer. Cancer Cell. 2017 11 13; 32(5):550-551.
    View in: PubMed
    Score: 0.012
  22. Molecular Subtypes of Non-muscle Invasive Bladder Cancer. Cancer Cell. 2016 07 11; 30(1):1-3.
    View in: PubMed
    Score: 0.011
  23. Bladder cancer: ASCO endorses EAU muscle-invasive bladder cancer guidelines. Nat Rev Urol. 2016 08; 13(8):440-1.
    View in: PubMed
    Score: 0.011
  24. Editorial Comment. J Urol. 2016 Jan; 195(1):59.
    View in: PubMed
    Score: 0.011
  25. Variability in surgical quality in a phase III clinical trial of radical cystectomy in patients with organ-confined, node-negative urothelial carcinoma of the bladder. J Surg Oncol. 2015 Jun; 111(7):923-8.
    View in: PubMed
    Score: 0.010
  26. Significance of lymphovascular invasion in organ-confined, node-negative urothelial cancer of the bladder: data from the prospective p53-MVAC trial. BJU Int. 2015 Jul; 116(1):44-9.
    View in: PubMed
    Score: 0.010
  27. Potential role for targeted therapy in muscle-invasive bladder cancer: lessons from the cancer genome atlas and beyond. Urol Clin North Am. 2015 May; 42(2):201-15, viii.
    View in: PubMed
    Score: 0.010
  28. Targeted therapies for metastatic bladder cancer. J Urol. 2015 Jan; 193(1):8-9.
    View in: PubMed
    Score: 0.010
  29. New imaging techniques for nonmuscle invasive bladder cancer. Curr Opin Urol. 2014 Sep; 24(5):532-9.
    View in: PubMed
    Score: 0.010
  30. Novel endoscopic diagnosis for bladder cancer. Cancer. 2015 Jan 15; 121(2):169-78.
    View in: PubMed
    Score: 0.010
  31. Bladder cancer: Always consider extravesical sites when BCG fails. Nat Rev Urol. 2014 Jan; 11(1):11-2.
    View in: PubMed
    Score: 0.009
  32. Innovations in radical cystectomy and pelvic lymph node dissection. Semin Oncol. 2012 Oct; 39(5):573-82.
    View in: PubMed
    Score: 0.009
  33. Strategies to prevent progression of high-risk bladder cancer at initial diagnosis. Curr Opin Urol. 2012 Sep; 22(5):405-14.
    View in: PubMed
    Score: 0.009
  34. Urine survivin as a diagnostic biomarker for bladder cancer: a systematic review. BJU Int. 2012 Sep; 110(5):630-6.
    View in: PubMed
    Score: 0.008
  35. Variables affecting long-term maintenance of renal function following ileal based urinary diversion. Eur Urol. 2012 Mar; 61(3):498-500; discussion 500-2.
    View in: PubMed
    Score: 0.008
  36. Highlights of the 2010 SUO Annual Meeting. Urol Oncol. 2011 Nov-Dec; 29(6):825.
    View in: PubMed
    Score: 0.008
  37. A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer. Cancer Prev Res (Phila). 2011 Oct; 4(10):1580-9.
    View in: PubMed
    Score: 0.008
  38. Positive margins after radical prostatectomy: implications for failure and role of adjuvant treatment. Urol Oncol. 2013 Jul; 31(5):531-41.
    View in: PubMed
    Score: 0.008
  39. Fluorescence and white light cystoscopy for detection of carcinoma in situ of the urinary bladder. Urol Oncol. 2012 May-Jun; 30(3):285-9.
    View in: PubMed
    Score: 0.008
  40. Editorial comment. J Urol. 2010 Jul; 184(1):79-80.
    View in: PubMed
    Score: 0.007
  41. BCAN Think Tank session 3: Prevention of bladder cancer. Urol Oncol. 2010 May-Jun; 28(3):338-42.
    View in: PubMed
    Score: 0.007
  42. Overview of SUO Winter 2008 proceedings. Urol Oncol. 2010 Jan-Feb; 28(1):67-8.
    View in: PubMed
    Score: 0.007
  43. Editorial comment. J Urol. 2010 Feb; 183(2):504.
    View in: PubMed
    Score: 0.007
  44. Innovations in endoscopic imaging for bladder cancer. Eur Urol. 2009 Dec; 56(6):920-2.
    View in: PubMed
    Score: 0.007
  45. The role and extent of pelvic lymphadenectomy in the management of patients with invasive urothelial carcinoma. Curr Treat Options Oncol. 2009 Aug; 10(3-4):267-74.
    View in: PubMed
    Score: 0.007
  46. Application of new technology in bladder cancer diagnosis and treatment. World J Urol. 2009 Jun; 27(3):301-7.
    View in: PubMed
    Score: 0.007
  47. Risk-adapted use of intravesical chemotherapy. BJU Int. 2008 Nov; 102(9 Pt B):1247-53.
    View in: PubMed
    Score: 0.007
  48. Prostatic biology, histologic patterns and clinical consequences of transitional cell carcinoma. Curr Opin Urol. 2008 Sep; 18(5):508-12.
    View in: PubMed
    Score: 0.006
  49. Pathologic assessment and clinical significance of prostatic involvement by transitional cell carcinoma and prostate cancer. Urol Oncol. 2008 Sep-Oct; 26(5):481-5.
    View in: PubMed
    Score: 0.006
  50. Occupational risk factors. Scand J Urol Nephrol Suppl. 2008 Sep; (218):58-63.
    View in: PubMed
    Score: 0.006
  51. Neoadjuvant chemotherapy preceding cystectomy for bladder cancer. Expert Opin Pharmacother. 2008 Aug; 9(11):1885-93.
    View in: PubMed
    Score: 0.006
  52. Optical coherence tomography as an adjunct to white light cystoscopy for intravesical real-time imaging and staging of bladder cancer. Urology. 2008 Jul; 72(1):133-7.
    View in: PubMed
    Score: 0.006
  53. Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model. Urol Oncol. 2009 Jul-Aug; 27(4):391-9.
    View in: PubMed
    Score: 0.006
  54. Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer. Urol Oncol. 2009 Mar-Apr; 27(2):155-9.
    View in: PubMed
    Score: 0.006
  55. Molecular markers in bladder cancer. Curr Opin Urol. 2008 Jan; 18(1):1-8.
    View in: PubMed
    Score: 0.006
  56. Neoadjuvant chemotherapy for bladder cancer. Oncology (Williston Park). 2007 Dec; 21(14):1673-81; discussion 1686-8, 1691, 1694.
    View in: PubMed
    Score: 0.006
  57. Prostatic transitional cell carcinoma: pathologic features and clinical management. Expert Rev Anticancer Ther. 2007 Aug; 7(8):1155-62.
    View in: PubMed
    Score: 0.006
  58. The use and abuse of data: nomograms and talking to patients about clinical medicine. Urol Oncol. 2007 Jul-Aug; 25(4):333-7.
    View in: PubMed
    Score: 0.006
  59. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer. J Urol. 2007 May; 177(5):1727-31.
    View in: PubMed
    Score: 0.006
  60. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol. 2006 Dec; 176(6 Pt 1):2414-22; discussion 2422.
    View in: PubMed
    Score: 0.006
  61. Nomograms provide improved accuracy for predicting survival after radical cystectomy. Clin Cancer Res. 2006 Nov 15; 12(22):6663-76.
    View in: PubMed
    Score: 0.006
  62. Chemoprevention of bladder cancer. World J Urol. 2006 Nov; 24(5):445-72.
    View in: PubMed
    Score: 0.006
  63. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. J Urol. 2006 Oct; 176(4 Pt 1):1354-61; discussion 1361-2.
    View in: PubMed
    Score: 0.006
  64. Treatment of high-risk, non-muscle-invasive bladder cancer. Nat Clin Pract Urol. 2006 Aug; 3(8):398-9.
    View in: PubMed
    Score: 0.006
  65. Advances in diagnosis and therapy of transitional cell carcinoma of the bladder. Urol Oncol. 2006 Jul-Aug; 24(4):324-5.
    View in: PubMed
    Score: 0.006
  66. Precystectomy nomogram for prediction of advanced bladder cancer stage. Eur Urol. 2006 Dec; 50(6):1254-60; discussion 1261-2.
    View in: PubMed
    Score: 0.006
  67. Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue. Cancer. 2006 Jun 15; 106(12):2610-6.
    View in: PubMed
    Score: 0.006
  68. Combining surgery and chemotherapy for invasive bladder cancer: current and future directions. Expert Rev Anticancer Ther. 2006 Feb; 6(2):281-91.
    View in: PubMed
    Score: 0.005
  69. Loss of coxsackie and adenovirus receptor expression is associated with features of aggressive bladder cancer. Urology. 2005 Aug; 66(2):441-6.
    View in: PubMed
    Score: 0.005
  70. Patients with unusual bladder malignancies and a rare cause of splenomegaly. Case 1. Small-cell carcinoma of the urinary bladder. J Clin Oncol. 2005 Jul 01; 23(19):4458-9.
    View in: PubMed
    Score: 0.005
  71. Patients with unusual bladder malignancies and a rare cause of splenomegaly. Case 2. Rhabdomyosarcoma of the urinary bladder in an adult. J Clin Oncol. 2005 Jul 01; 23(19):4459-60.
    View in: PubMed
    Score: 0.005
  72. Bladder cancer clinical trials. Urol Oncol. 2005 Jul-Aug; 23(4):275-9.
    View in: PubMed
    Score: 0.005
  73. Urinary levels of soluble e-cadherin in the detection of transitional cell carcinoma of the urinary bladder. Eur Urol. 2005 Jul; 48(1):69-76.
    View in: PubMed
    Score: 0.005
  74. Alternatives to cytology in the management of non-muscle invasive bladder cancer. Curr Treat Options Oncol. 2004 Oct; 5(5):377-89.
    View in: PubMed
    Score: 0.005
  75. Stage specific lymph node metastasis mapping in radical cystectomy specimens. J Urol. 2004 May; 171(5):1830-4.
    View in: PubMed
    Score: 0.005
  76. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol. 2004 Mar 15; 22(6):1014-24.
    View in: PubMed
    Score: 0.005
  77. The IL6/JAK/STAT3 signaling axis is a therapeutic vulnerability in SMARCB1-deficient bladder cancer. Nat Commun. 2024 Feb 14; 15(1):1373.
    View in: PubMed
    Score: 0.005
  78. Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J Urol. 2004 Feb; 171(2 Pt 1):626-30.
    View in: PubMed
    Score: 0.005
  79. Granulocyte colony-stimulating factor receptor signals for beta1-integrin expression and adhesion in bladder cancer. Urology. 2004 Jan; 63(1):177-83.
    View in: PubMed
    Score: 0.005
  80. The addition of urinary urokinase-type plasminogen activator to urinary nuclear matrix protein 22 and cytology improves the detection of bladder cancer. J Urol. 2003 Dec; 170(6 Pt 1):2244-7.
    View in: PubMed
    Score: 0.005
  81. Preoperative plasma soluble E-cadherin predicts metastases to lymph nodes and prognosis in patients undergoing radical cystectomy. J Urol. 2003 Dec; 170(6 Pt 1):2248-52.
    View in: PubMed
    Score: 0.005
  82. Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group. J Clin Oncol. 2023 Dec 10; 41(35):5437-5447.
    View in: PubMed
    Score: 0.005
  83. Bacillus Calmette-Gu?rin vaccination as defense against SARS-CoV-2 (BADAS): a randomized controlled trial to protect healthcare workers in the USA by enhanced trained immune responses. Trials. 2023 Oct 04; 24(1):636.
    View in: PubMed
    Score: 0.005
  84. Correlation of cyclooxygenase-2 expression with molecular markers, pathological features and clinical outcome of transitional cell carcinoma of the bladder. J Urol. 2003 Sep; 170(3):985-9.
    View in: PubMed
    Score: 0.005
  85. Perioperative chemotherapy in locally advanced bladder cancer. Lancet. 2003 Jun 07; 361(9373):1922-3.
    View in: PubMed
    Score: 0.005
  86. Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. Urology. 2003 Jun; 61(6):1140-5.
    View in: PubMed
    Score: 0.005
  87. Epidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors. Eur Urol. 2023 08; 84(2):176-190.
    View in: PubMed
    Score: 0.005
  88. Combination of adenovirus-mediated thymidine kinase gene therapy with cytotoxic chemotherapy in bladder cancer in vitro. Urol Oncol. 2003 May-Jun; 21(3):197-205.
    View in: PubMed
    Score: 0.004
  89. Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314. Eur Urol Oncol. 2023 10; 6(5):516-524.
    View in: PubMed
    Score: 0.004
  90. Circulating and urinary tumour DNA in urothelial carcinoma?- upper tract, lower tract and metastatic disease. Nat Rev Urol. 2023 07; 20(7):406-419.
    View in: PubMed
    Score: 0.004
  91. Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder. J Urol. 2003 Mar; 169(3):938-42.
    View in: PubMed
    Score: 0.004
  92. Association Between Antibiotic Prophylaxis Before Cystectomy or Stent Removal and Infection Complications: A Systematic Review. Eur Urol Focus. 2023 07; 9(4):631-636.
    View in: PubMed
    Score: 0.004
  93. Urinary levels of urokinase-type plasminogen activator and its receptor in the detection of bladder carcinoma. Cancer. 2002 Dec 15; 95(12):2494-9.
    View in: PubMed
    Score: 0.004
  94. Targeting FGFR3 alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial. Future Oncol. 2022 Jul; 18(21):2599-2614.
    View in: PubMed
    Score: 0.004
  95. Considerations on Integrating Prostate-Specific Membrane Antigen Positron Emission Tomography Imaging Into Clinical Prostate Cancer Trials by National Clinical Trials Network Cooperative Groups. J Clin Oncol. 2022 05 01; 40(13):1500-1505.
    View in: PubMed
    Score: 0.004
  96. International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Gu?rin-exposed High-risk Non-muscle-invasive Bladder Cancer. Eur Urol. 2022 07; 82(1):34-46.
    View in: PubMed
    Score: 0.004
  97. Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial. Eur Urol. 2022 03; 81(3):223-228.
    View in: PubMed
    Score: 0.004
  98. Predictive value of expression of transforming growth factor-beta(1) and its receptors in transitional cell carcinoma of the urinary bladder. Cancer. 2001 Sep 15; 92(6):1475-83.
    View in: PubMed
    Score: 0.004
  99. Refining neoadjuvant therapy clinical trial design for muscle-invasive bladder cancer before cystectomy: a joint US Food and Drug Administration and Bladder Cancer Advocacy Network workshop. Nat Rev Urol. 2022 01; 19(1):37-46.
    View in: PubMed
    Score: 0.004
  100. E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup. J Urol. 2001 May; 165(5):1473-9.
    View in: PubMed
    Score: 0.004
  101. Surgical challenges and considerations in Tri-modal therapy for muscle invasive bladder cancer. Urol Oncol. 2022 10; 40(10):442-450.
    View in: PubMed
    Score: 0.004
  102. A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695). Clin Cancer Res. 2021 05 01; 27(9):2435-2441.
    View in: PubMed
    Score: 0.004
  103. Rebuilding the lower urinary tract after cystectomy: a roadmap for patient selection and counseling. Semin Urol Oncol. 2001 Feb; 19(1):24-36.
    View in: PubMed
    Score: 0.004
  104. The Who, What, When, Where, and Why of Bacillus Calmette-Gu?rin-unresponsive Bladder Cancer. Eur Urol. 2021 04; 79(4):437-439.
    View in: PubMed
    Score: 0.004
  105. E-cadherin expression predicts clinical outcome in carcinoma in situ of the urinary bladder. Urology. 2001 Jan; 57(1):60-5.
    View in: PubMed
    Score: 0.004
  106. Glut 1 expression in transitional cell carcinoma of the urinary bladder is associated with poor patient survival. Anticancer Res. 2001 Jan-Feb; 21(1B):575-8.
    View in: PubMed
    Score: 0.004
  107. Genetic Differences Between Bladder and Upper Urinary Tract Carcinoma: Implications for Therapy. Eur Urol Oncol. 2021 04; 4(2):170-179.
    View in: PubMed
    Score: 0.004
  108. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 2021 01; 22(1):107-117.
    View in: PubMed
    Score: 0.004
  109. Prognostic value of P53 nuclear accumulation and histopathologic features in T1 transitional cell carcinoma of the urinary bladder. Urology. 2000 Nov 01; 56(5):735-40.
    View in: PubMed
    Score: 0.004
  110. In vivo adenovirus-mediated suicide gene therapy of orthotopic bladder cancer. Mol Ther. 2000 Sep; 2(3):211-7.
    View in: PubMed
    Score: 0.004
  111. Adenovirus-mediated suicide gene therapy for bladder cancer: comparison of the cytomegalovirus- and Rous sarcoma virus-promoter. Anticancer Res. 2000 Sep-Oct; 20(5A):2811-6.
    View in: PubMed
    Score: 0.004
  112. Outreach and Influence of Surgical Societies' Recommendations on Minimally Invasive Surgery During the COVID-19 Pandemic-An Anonymized International Urologic Expert Inquiry. Urology. 2020 11; 145:73-78.
    View in: PubMed
    Score: 0.004
  113. Evidence-based Assessment of Current and Emerging Bladder-sparing Therapies for Non-muscle-invasive Bladder Cancer After Bacillus Calmette-Guerin Therapy: A Systematic Review and Meta-analysis. Eur Urol Oncol. 2020 06; 3(3):318-340.
    View in: PubMed
    Score: 0.004
  114. Transurethral Resection of Bladder Tumour: The Neglected Procedure in the Technology Race in Bladder Cancer. Eur Urol. 2020 06; 77(6):669-670.
    View in: PubMed
    Score: 0.004
  115. Reply To Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer: A Step in the Right Direction but Still a Long Way To Go. Eur Urol 2020;77:434-5. Eur Urol. 2020 04; 77(4):436-438.
    View in: PubMed
    Score: 0.004
  116. Eligibility and Radiologic Assessment in Adjuvant Clinical Trials in Bladder Cancer. JAMA Oncol. 2019 12 01; 5(12):1790-1798.
    View in: PubMed
    Score: 0.004
  117. Weighted Gleason Grade Group (WGGG): A new prostate cancer biopsy reporting system with prognostic potential. Urol Oncol. 2020 03; 38(3):78.e15-78.e21.
    View in: PubMed
    Score: 0.004
  118. DNA methylation patterns in bladder tumors of African American patients point to distinct alterations in xenobiotic metabolism. Carcinogenesis. 2019 11 25; 40(11):1332-1340.
    View in: PubMed
    Score: 0.004
  119. Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials. Clin Cancer Res. 2020 02 15; 26(4):882-891.
    View in: PubMed
    Score: 0.004
  120. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. Eur Urol. 2020 04; 77(4):420-433.
    View in: PubMed
    Score: 0.003
  121. Decreased expression of transforming growth factor beta receptor type I is associated with poor prognosis in bladder transitional cell carcinoma patients. Clin Cancer Res. 1999 Sep; 5(9):2520-5.
    View in: PubMed
    Score: 0.003
  122. Renal cell carcinoma with an infrarenal vena caval tumor thrombus. Urology. 1999 Sep; 54(3):561.
    View in: PubMed
    Score: 0.003
  123. Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. Nat Commun. 2019 07 05; 10(1):2977.
    View in: PubMed
    Score: 0.003
  124. Molecular Subtyping of Clinically Localized Urothelial Carcinoma Reveals Lower Rates of Pathological Upstaging at Radical Cystectomy Among Luminal Tumors. Eur Urol. 2019 08; 76(2):200-206.
    View in: PubMed
    Score: 0.003
  125. Multi-omics Integration Analysis Robustly Predicts High-Grade Patient Survival and Identifies CPT1B Effect on Fatty Acid Metabolism in Bladder Cancer. Clin Cancer Res. 2019 06 15; 25(12):3689-3701.
    View in: PubMed
    Score: 0.003
  126. Endocavitary treatment for upper tract urothelial carcinoma: A meta-analysis of the current literature. Urol Oncol. 2019 07; 37(7):430-436.
    View in: PubMed
    Score: 0.003
  127. Pathological features and prognostic significance of prostate cancer in the apical section determined by whole mount histology. J Urol. 1999 Feb; 161(2):500-4.
    View in: PubMed
    Score: 0.003
  128. Renal cell carcinoma and situs inversus viscerum. J Urol. 1998 Dec; 160(6 Pt 1):2141-2.
    View in: PubMed
    Score: 0.003
  129. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). Eur Urol. 2018 09; 74(3):294-306.
    View in: PubMed
    Score: 0.003
  130. Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial. JAMA. 2018 05 08; 319(18):1880-1888.
    View in: PubMed
    Score: 0.003
  131. Is folic acid safe for non-muscle-invasive bladder cancer patients? An evidence-based cohort study. Am J Clin Nutr. 2018 02 01; 107(2):208-216.
    View in: PubMed
    Score: 0.003
  132. Dietary patterns and risk of recurrence and progression in non-muscle-invasive bladder cancer. Int J Cancer. 2018 05 01; 142(9):1797-1804.
    View in: PubMed
    Score: 0.003
  133. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell. 2017 Oct 19; 171(3):540-556.e25.
    View in: PubMed
    Score: 0.003
  134. Fifteen-year survival and recurrence rates after radiotherapy for localized prostate cancer. J Clin Oncol. 1997 Oct; 15(10):3214-22.
    View in: PubMed
    Score: 0.003
  135. Current status of gene therapy for prostate and bladder cancer. Int J Urol. 1997 Sep; 4(5):435-40.
    View in: PubMed
    Score: 0.003
  136. Tobacco-Specific Carcinogens Induce Hypermethylation, DNA Adducts, and DNA Damage in Bladder Cancer. Cancer Prev Res (Phila). 2017 Oct; 10(10):588-597.
    View in: PubMed
    Score: 0.003
  137. Intravesical rAd-IFNa/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. J Clin Oncol. 2017 Oct 20; 35(30):3410-3416.
    View in: PubMed
    Score: 0.003
  138. Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: American Urological Association/American Society of Clinical Oncology/American Society for Radiation Oncology/Society of Urologic Oncology Clinical Practice Guideline Summary. J Oncol Pract. 2017 09; 13(9):621-625.
    View in: PubMed
    Score: 0.003
  139. Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma. Eur Urol. 2017 10; 72(4):641-649.
    View in: PubMed
    Score: 0.003
  140. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline. J Urol. 2017 09; 198(3):552-559.
    View in: PubMed
    Score: 0.003
  141. Distinct Lipidomic Landscapes Associated with Clinical Stages of Urothelial Cancer of the Bladder. Eur Urol Focus. 2018 12; 4(6):907-915.
    View in: PubMed
    Score: 0.003
  142. Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy. Eur Urol. 2017 10; 72(4):544-554.
    View in: PubMed
    Score: 0.003
  143. Conservative management of spontaneous rupture of Kock orthotopic ileal reservoir. Urology. 1997 Apr; 49(4):629-31.
    View in: PubMed
    Score: 0.003
  144. Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset. Eur Urol. 2017 09; 72(3):354-365.
    View in: PubMed
    Score: 0.003
  145. Aurora Kinase A is a Biomarker for Bladder Cancer Detection and Contributes to its Aggressive Behavior. Sci Rep. 2017 01 19; 7:40714.
    View in: PubMed
    Score: 0.003
  146. Bacillus Calmette-Gu?rin Manufacturing and SWOG S1602 Intergroup Clinical Trial. J Urol. 2017 03; 197(3 Pt 1):538-540.
    View in: PubMed
    Score: 0.003
  147. Positive association of collagen type I with non-muscle invasive bladder cancer progression. Oncotarget. 2016 Dec 13; 7(50):82609-82619.
    View in: PubMed
    Score: 0.003
  148. Urinary tract reconstruction--the expanding surgical armamentarium. J Urol. 1996 Dec; 156(6):1929-30.
    View in: PubMed
    Score: 0.003
  149. Neutrophil-to-lymphocyte ratio as a bladder cancer biomarker: Assessing prognostic and predictive value in SWOG 8710. Cancer. 2017 Mar 01; 123(5):794-801.
    View in: PubMed
    Score: 0.003
  150. Diagnostic and Prognostic Markers in Bladder Cancer. Dis Markers. 2016; 2016:2425091.
    View in: PubMed
    Score: 0.003
  151. Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). World J Urol. 2017 Mar; 35(3):379-387.
    View in: PubMed
    Score: 0.003
  152. The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics. Eur Urol. 2017 02; 71(2):237-246.
    View in: PubMed
    Score: 0.003
  153. Bladder cancer. Lancet. 2016 12 03; 388(10061):2796-2810.
    View in: PubMed
    Score: 0.003
  154. Prognostic Significance of Neutrophilic Infiltration in Benign Lymph Nodes in Patients with Muscle-invasive Bladder Cancer. Eur Urol Focus. 2017 02; 3(1):130-135.
    View in: PubMed
    Score: 0.003
  155. The case for salvage cystectomy after pelvic radiation. Minerva Urol Nefrol. 2016 Apr; 68(2):161-71.
    View in: PubMed
    Score: 0.003
  156. Incidence and prognostic impact of other cancers in a population of long-term survivors of chronic lymphocytic leukemia. Ann Oncol. 2016 06; 27(6):1100-1106.
    View in: PubMed
    Score: 0.003
  157. Testis cancer--progress in risk assessment for occult retroperitoneal lymph node metastases. J Urol. 1996 Feb; 155(2):593-4.
    View in: PubMed
    Score: 0.003
  158. Validating a Local Failure Risk Stratification for Use in Prospective Studies of Adjuvant Radiation Therapy for Bladder Cancer. Int J Radiat Oncol Biol Phys. 2016 06 01; 95(2):703-6.
    View in: PubMed
    Score: 0.003
  159. Integrative Pathway Analysis of Metabolic Signature in Bladder Cancer: A Linkage to The Cancer Genome Atlas Project and Prediction of Survival. J Urol. 2016 06; 195(6):1911-9.
    View in: PubMed
    Score: 0.003
  160. Invasive Bladder Cancer: Genomic Insights and Therapeutic Promise. Clin Cancer Res. 2015 Oct 15; 21(20):4514-24.
    View in: PubMed
    Score: 0.003
  161. Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activity. Urol Oncol. 2016 Jan; 34(1):4.e11-7.
    View in: PubMed
    Score: 0.003
  162. External Validation of Bladder Cancer Predictive Nomograms for Recurrence, Cancer-Free Survival and Overall Survival following Radical Cystectomy. J Urol. 2016 Feb; 195(2):283-9.
    View in: PubMed
    Score: 0.003
  163. The role of surgery in the management of pediatric pelvic rhabdomyosarcoma. J Urol. 1995 Aug; 154(2 Pt 1):540-5.
    View in: PubMed
    Score: 0.003
  164. New trends in the surgical management of invasive bladder cancer. Hematol Oncol Clin North Am. 2015 Apr; 29(2):253-69, viii.
    View in: PubMed
    Score: 0.003
  165. Prognostic and Prediction Tools in Bladder Cancer: A Comprehensive Review of the Literature. Eur Urol. 2015 Aug; 68(2):238-53.
    View in: PubMed
    Score: 0.003
  166. Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance. Nature. 2015 Jan 08; 517(7533):209-13.
    View in: PubMed
    Score: 0.003
  167. Educational opportunities in bladder cancer: increasing cystoscopic adherence and the availability of smoking-cessation programs. J Cancer Educ. 2014 Dec; 29(4):739-45.
    View in: PubMed
    Score: 0.003
  168. Renal cell carcinoma extending into the retrohepatic inferior vena cava. Tex Heart Inst J. 2014 Dec; 41(6):671-2.
    View in: PubMed
    Score: 0.003
  169. Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute Forum. Urol Oncol. 2014 Nov; 32(8):1108-15.
    View in: PubMed
    Score: 0.002
  170. Activity of CEP-9722, a poly (ADP-ribose) polymerase inhibitor, in urothelial carcinoma correlates inversely with homologous recombination repair response to DNA damage. Anticancer Drugs. 2014 Sep; 25(8):878-86.
    View in: PubMed
    Score: 0.002
  171. Usefulness of transurethral biopsy for staging the prostatic urethra before radical cystectomy. J Urol. 2015 Jan; 193(1):58-63.
    View in: PubMed
    Score: 0.002
  172. Reply by the authors. Urology. 2014 Aug; 84(2):495-6.
    View in: PubMed
    Score: 0.002
  173. Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. Hum Mol Genet. 2014 Dec 15; 23(24):6616-33.
    View in: PubMed
    Score: 0.002
  174. The angiopoietin-TIE2 pathway is a potential therapeutic target in urothelial carcinoma. Anticancer Res. 2014 Jul; 34(7):3377-82.
    View in: PubMed
    Score: 0.002
  175. The preclinical activity of lenalidomide in indolent urothelial carcinoma. Anticancer Res. 2014 Jul; 34(7):3383-9.
    View in: PubMed
    Score: 0.002
  176. Female gender is associated with a worse survival after radical cystectomy for urothelial carcinoma of the bladder: a competing risk analysis. Urology. 2014 Apr; 83(4):863-7.
    View in: PubMed
    Score: 0.002
  177. Can laparoscopic cholecystectomy be performed with a positive margin at medicaid reimbursement rates? J Am Coll Surg. 2014 Apr; 218(4):546-51.
    View in: PubMed
    Score: 0.002
  178. Optimizing bladder cancer locoregional failure risk stratification after radical cystectomy using SWOG 8710. Cancer. 2014 Apr 15; 120(8):1272-80.
    View in: PubMed
    Score: 0.002
  179. Urinary diversion after radical cystectomy for bladder cancer: options, patient selection, and outcomes. BJU Int. 2014 Jan; 113(1):11-23.
    View in: PubMed
    Score: 0.002
  180. Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: report of a Food and Drug Administration and American Urological Association public workshop. Urology. 2014 Feb; 83(2):262-4.
    View in: PubMed
    Score: 0.002
  181. Genome-wide association study identifies multiple loci associated with bladder cancer risk. Hum Mol Genet. 2014 Mar 01; 23(5):1387-98.
    View in: PubMed
    Score: 0.002
  182. Lymphadenectomy for bladder cancer at the time of radical cystectomy. Eur Urol. 2013 Aug; 64(2):266-76.
    View in: PubMed
    Score: 0.002
  183. SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Gu?rin. J Urol. 2013 Oct; 190(4):1200-4.
    View in: PubMed
    Score: 0.002
  184. The rationale for en bloc pelvic lymph node dissection for bladder cancer patients with nodal metastases: long-term results. J Urol. 1993 Apr; 149(4):758-64; discussion 764-5.
    View in: PubMed
    Score: 0.002
  185. Critical analysis of contemporary clinical research in muscle-invasive and metastatic urothelial cancer: a report from the Bladder Cancer Advocacy Network Clinical Trials Working Group. Cancer. 2013 Jun 01; 119(11):1994-8.
    View in: PubMed
    Score: 0.002
  186. Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer. Clin Genitourin Cancer. 2013 Jun; 11(2):175-81.
    View in: PubMed
    Score: 0.002
  187. Lymphovascular invasion is independently associated with bladder cancer recurrence and survival in patients with final stage T1 disease and negative lymph nodes after radical cystectomy. BJU Int. 2013 Jun; 111(8):1215-21.
    View in: PubMed
    Score: 0.002
  188. Radical cystectomy in regionally advanced bladder cancer. Urol Clin North Am. 1992 Nov; 19(4):713-23.
    View in: PubMed
    Score: 0.002
  189. A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer. J Urol. 2012 Dec; 188(6):2391-7.
    View in: PubMed
    Score: 0.002
  190. Raloxifene inhibits growth of RT4 urothelial carcinoma cells via estrogen receptor-dependent induction of apoptosis and inhibition of proliferation. Horm Cancer. 2013 Feb; 4(1):24-35.
    View in: PubMed
    Score: 0.002
  191. Plagiarism. Urol Oncol. 2012 Sep; 30(5):547-8.
    View in: PubMed
    Score: 0.002
  192. ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2013 Jan; 63(1):45-57.
    View in: PubMed
    Score: 0.002
  193. A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol. 2012 Sep; 62(3):523-33.
    View in: PubMed
    Score: 0.002
  194. Perioperative chemotherapy for upper tract urothelial cancer. Nat Rev Urol. 2012 Apr 10; 9(5):266-73.
    View in: PubMed
    Score: 0.002
  195. Three differentiation states risk-stratify bladder cancer into distinct subtypes. Proc Natl Acad Sci U S A. 2012 Feb 07; 109(6):2078-83.
    View in: PubMed
    Score: 0.002
  196. Racial/ethnic differences in upper-tract urothelial cancer. Ethn Dis. 2012; 22(3):295-301.
    View in: PubMed
    Score: 0.002
  197. The risk of dying of prostate cancer in patients with clinically localized disease. J Urol. 1991 Oct; 146(4):1040-5.
    View in: PubMed
    Score: 0.002
  198. A genome-wide association study of bladder cancer identifies a new susceptibility locus within SLC14A1, a urea transporter gene on chromosome 18q12.3. Hum Mol Genet. 2011 Nov 01; 20(21):4282-9.
    View in: PubMed
    Score: 0.002
  199. Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol. 2011 Sep 01; 29(25):3443-9.
    View in: PubMed
    Score: 0.002
  200. A conventional preclinical schedule of cisplatin is more effective than a metronomic frequent bolus schedule for urothelial carcinoma. Urol Oncol. 2013 Feb; 31(2):234-40.
    View in: PubMed
    Score: 0.002
  201. Critical analysis and validation of lymph node density as prognostic variable in urothelial carcinoma of bladder. Urol Oncol. 2013 May; 31(4):480-6.
    View in: PubMed
    Score: 0.002
  202. Prognostic risk stratification of pathological stage T3N0 bladder cancer after radical cystectomy. J Urol. 2011 Apr; 185(4):1216-21.
    View in: PubMed
    Score: 0.002
  203. Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer. J Urol. 2011 Feb; 185(2):456-61.
    View in: PubMed
    Score: 0.002
  204. Prognostic risk stratification of pathological stage T2N0 bladder cancer after radical cystectomy. BJU Int. 2011 Sep; 108(5):687-92.
    View in: PubMed
    Score: 0.002
  205. Stage pT0 at radical cystectomy confers improved survival: an international study of 4,430 patients. J Urol. 2010 Sep; 184(3):888-94.
    View in: PubMed
    Score: 0.002
  206. The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. Clin Cancer Res. 2010 Sep 01; 16(17):4461-7.
    View in: PubMed
    Score: 0.002
  207. Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of more than 4,400 patients. J Urol. 2010 Jun; 183(6):2165-70.
    View in: PubMed
    Score: 0.002
  208. A critical analysis of orthotopic bladder substitutes in adult patients with bladder cancer: is there a perfect solution? Eur Urol. 2010 Sep; 58(3):374-83.
    View in: PubMed
    Score: 0.002
  209. Dasatinib is preclinically active against Src-overexpressing human transitional cell carcinoma of the urothelium with activated Src signaling. Mol Cancer Ther. 2010 May; 9(5):1128-35.
    View in: PubMed
    Score: 0.002
  210. Characteristics and outcomes of patients with clinical carcinoma in situ only treated with radical cystectomy: an international study of 243 patients. J Urol. 2010 May; 183(5):1757-63.
    View in: PubMed
    Score: 0.002
  211. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin Chem. 2010 Jun; 56(6):e1-48.
    View in: PubMed
    Score: 0.002
  212. Prevention and management of complications following radical cystectomy for bladder cancer. Eur Urol. 2010 Jun; 57(6):983-1001.
    View in: PubMed
    Score: 0.002
  213. Accuracy of the extent of bladder cancer nodal metastases found at pelvic lymphadenectomy at the time of cystectomy: relation to primary tumor stage. Urol Int. 2010; 84(1):14-22.
    View in: PubMed
    Score: 0.002
  214. International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. BJU Int. 2010 May; 105(10):1402-12.
    View in: PubMed
    Score: 0.002
  215. Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. J Urol. 2010 Jan; 183(1):68-75.
    View in: PubMed
    Score: 0.002
  216. Characteristics and outcomes of patients with pT4 urothelial carcinoma at radical cystectomy: a retrospective international study of 583 patients. J Urol. 2010 Jan; 183(1):87-93.
    View in: PubMed
    Score: 0.002
  217. Bladder cancer detection, treatment and outcomes: opportunities and challenges. Urology. 2010 Feb; 75(2):334-9.
    View in: PubMed
    Score: 0.002
  218. Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer. 2009 Sep 15; 115(18):4104-9.
    View in: PubMed
    Score: 0.002
  219. Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Eur Urol. 2010 Feb; 57(2):300-9.
    View in: PubMed
    Score: 0.002
  220. p53 expression in patients with advanced urothelial cancer of the urinary bladder. BJU Int. 2010 Feb; 105(4):489-95.
    View in: PubMed
    Score: 0.002
  221. p53 predictive value for pT1-2 N0 disease at radical cystectomy. J Urol. 2009 Sep; 182(3):907-13.
    View in: PubMed
    Score: 0.002
  222. Residual pathological stage at radical cystectomy significantly impacts outcomes for initial T2N0 bladder cancer. J Urol. 2009 Aug; 182(2):459-65; discussion 465.
    View in: PubMed
    Score: 0.002
  223. Enzastaurin shows preclinical antitumor activity against human transitional cell carcinoma and enhances the activity of gemcitabine. Mol Cancer Ther. 2009 Jul; 8(7):1772-8.
    View in: PubMed
    Score: 0.002
  224. Outcome of combined liver and kidney transplantation in hepatitis C: a single-center long-term follow-up experience. Transplant Proc. 2009 Jun; 41(5):1713-6.
    View in: PubMed
    Score: 0.002
  225. Infection stones. J Urol. 1989 Mar; 141(3 Pt 2):753-8.
    View in: PubMed
    Score: 0.002
  226. Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer. J Natl Cancer Inst. 2009 Jan 21; 101(2):114-9.
    View in: PubMed
    Score: 0.002
  227. Assessing the minimum number of lymph nodes needed at radical cystectomy in patients with bladder cancer. BJU Int. 2009 May; 103(10):1359-62.
    View in: PubMed
    Score: 0.002
  228. Bladder cancer today. BJU Int. 2008 Nov; 102(9 Pt B):1203.
    View in: PubMed
    Score: 0.002
  229. Adjuvant chemotherapy for bladder cancer does not alter cancer-specific survival after cystectomy in a matched case-control study. BJU Int. 2008 Jun; 101(11):1356-61.
    View in: PubMed
    Score: 0.002
  230. Safety and side effects of immediate instillation of apaziquone following transurethral resection in patients with nonmuscle invasive bladder cancer. J Urol. 2008 Jul; 180(1):116-20.
    View in: PubMed
    Score: 0.002
  231. Outcomes of patients with clinical T1 grade 3 urothelial cell bladder carcinoma treated with radical cystectomy. Urology. 2008 Feb; 71(2):302-7.
    View in: PubMed
    Score: 0.002
  232. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer. 2008 Jan 15; 112(2):315-25.
    View in: PubMed
    Score: 0.002
  233. Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer. Clin Cancer Res. 2008 Jan 01; 14(1):224-9.
    View in: PubMed
    Score: 0.002
  234. Novel agents for muscle-invasive and advanced urothelial cancer. BJU Int. 2008 Apr; 101(8):937-43.
    View in: PubMed
    Score: 0.002
  235. Macroscopic, but not microscopic, perivesical fat invasion at radical cystectomy is an adverse predictor of recurrence and survival. BJU Int. 2008 Feb; 101(4):450-4.
    View in: PubMed
    Score: 0.002
  236. A delay in radical cystectomy of >3 months is not associated with a worse clinical outcome. BJU Int. 2007 Nov; 100(5):1015-20.
    View in: PubMed
    Score: 0.002
  237. High-order interactions among genetic polymorphisms in nucleotide excision repair pathway genes and smoking in modulating bladder cancer risk. Carcinogenesis. 2007 Oct; 28(10):2160-5.
    View in: PubMed
    Score: 0.002
  238. Efficacy of selective estrogen receptor modulators in nude mice bearing human transitional cell carcinoma. Urology. 2007 Jun; 69(6):1221-6.
    View in: PubMed
    Score: 0.001
  239. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J Urol. 2007 Jul; 178(1):68-73; discussion 73.
    View in: PubMed
    Score: 0.001
  240. Urothelial carcinoma of the prostate. Urology. 2007 Jan; 69(1 Suppl):50-61.
    View in: PubMed
    Score: 0.001
  241. Advanced age is associated with poorer bladder cancer-specific survival in patients treated with radical cystectomy. Eur Urol. 2007 Mar; 51(3):699-706; discussion 706-8.
    View in: PubMed
    Score: 0.001
  242. Characteristics and outcomes of patients with carcinoma in situ only at radical cystectomy. Urology. 2006 Sep; 68(3):538-42.
    View in: PubMed
    Score: 0.001
  243. Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ-confined TCC at radical cystectomy. Eur Urol. 2007 Jan; 51(1):152-60.
    View in: PubMed
    Score: 0.001
  244. Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort. Clin Cancer Res. 2006 Aug 15; 12(16):4872-5.
    View in: PubMed
    Score: 0.001
  245. Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Eur Urol. 2007 Jan; 51(1):137-49; discussion 149-51.
    View in: PubMed
    Score: 0.001
  246. Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder. J Urol. 2006 Jun; 175(6):2048-53; discussion 2053.
    View in: PubMed
    Score: 0.001
  247. Prostatic involvement by transitional cell carcinoma in patients with bladder cancer and its prognostic significance. Hum Pathol. 2006 Jun; 37(6):726-34.
    View in: PubMed
    Score: 0.001
  248. Cancer specific outcomes in patients with pT0 disease following radical cystectomy. J Urol. 2006 May; 175(5):1645-9; discussion 1649.
    View in: PubMed
    Score: 0.001
  249. Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of l-selenomethionine: a Southwest Oncology Group Study. Clin Cancer Res. 2006 Apr 01; 12(7 Pt 1):2178-84.
    View in: PubMed
    Score: 0.001
  250. Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes. Am J Hum Genet. 2006 Mar; 78(3):464-79.
    View in: PubMed
    Score: 0.001
  251. Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia. Leukemia. 2005 Oct; 19(10):1788-93.
    View in: PubMed
    Score: 0.001
  252. Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. J Clin Oncol. 2005 Sep 20; 23(27):6533-9.
    View in: PubMed
    Score: 0.001
  253. Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival. J Clin Oncol. 2005 Aug 20; 23(24):5746-56.
    View in: PubMed
    Score: 0.001
  254. Calcium oxalate deposition in renal cell carcinoma associated with acquired cystic kidney disease: a comprehensive study. Am J Surg Pathol. 2005 Apr; 29(4):443-51.
    View in: PubMed
    Score: 0.001
  255. Polymorphisms in XPD exons 10 and 23 and bladder cancer risk. Cancer Epidemiol Biomarkers Prev. 2005 Apr; 14(4):878-84.
    View in: PubMed
    Score: 0.001
  256. Case-control analysis of dietary folate and risk of bladder cancer. Nutr Cancer. 2005; 53(2):144-51.
    View in: PubMed
    Score: 0.001
  257. Dietary carotenoids and genetic instability modify bladder cancer risk. J Nutr. 2004 Dec; 134(12):3362-9.
    View in: PubMed
    Score: 0.001
  258. Restoration of bone morphogenetic protein receptor type II expression leads to a decreased rate of tumor growth in bladder transitional cell carcinoma cell line TSU-Pr1. Cancer Res. 2004 Oct 15; 64(20):7355-60.
    View in: PubMed
    Score: 0.001
  259. Standardization of radical cystectomy and pelvic lymph node dissection for bladder cancer: a collaborative group report. J Urol. 2004 May; 171(5):1823-8; discussion 1827-8.
    View in: PubMed
    Score: 0.001
  260. Centrosomal abnormality is common in and a potential biomarker for bladder cancer. Int J Cancer. 2003 Sep 20; 106(5):661-5.
    View in: PubMed
    Score: 0.001
  261. Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder. Urology. 2003 May; 61(5):1053-8.
    View in: PubMed
    Score: 0.001
  262. Bladder cancer screening program for a petrochemical cohort with potential exposure to beta-napthylamine. J Occup Environ Med. 2003 Mar; 45(3):289-94.
    View in: PubMed
    Score: 0.001
  263. Plasma levels of insulin-like growth factor-1 and binding protein-3, and their association with bladder cancer risk. J Urol. 2003 Feb; 169(2):714-7.
    View in: PubMed
    Score: 0.001
  264. Correlation of preoperative levels of IGF-I and IGFBP-3 with pathologic parameters and clinical outcome in patients with bladder cancer. Urology. 2003 Feb; 61(2):359-64.
    View in: PubMed
    Score: 0.001
  265. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma. 2002 Sep; 43(9):1755-62.
    View in: PubMed
    Score: 0.001
  266. Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma. Cancer. 2001 Dec 15; 92(12):2985-92.
    View in: PubMed
    Score: 0.001
  267. Society of Urologic Oncology Biotechnology Forum: new approaches and targets for advanced prostate cancer. J Urol. 2001 Oct; 166(4):1316-21.
    View in: PubMed
    Score: 0.001
  268. Higher levels of surface CD20 expression on circulating lymphocytes compared with bone marrow and lymph nodes in B-cell chronic lymphocytic leukemia. Am J Clin Pathol. 2001 Sep; 116(3):437-43.
    View in: PubMed
    Score: 0.001
  269. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood. 2001 Jul 01; 98(1):181-6.
    View in: PubMed
    Score: 0.001
  270. Retrospective study of the prognostic role of serum thymidine kinase level in CLL patients with active disease treated with fludarabine. Ann Oncol. 2001 May; 12(5):621-5.
    View in: PubMed
    Score: 0.001
  271. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst. 2001 Apr 18; 93(8):597-604.
    View in: PubMed
    Score: 0.001
  272. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol. 2001 Apr 15; 19(8):2165-70.
    View in: PubMed
    Score: 0.001
  273. High levels of vascular endothelial growth factor receptor-2 correlate with shortened survival in chronic lymphocytic leukemia. Clin Cancer Res. 2001 Apr; 7(4):795-9.
    View in: PubMed
    Score: 0.001
  274. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol. 2001 Mar 01; 19(5):1414-20.
    View in: PubMed
    Score: 0.001
  275. Giant bilateral renal angiomyolipomas associated with tuberous sclerosis. Urology. 2001 Mar; 57(3):554.
    View in: PubMed
    Score: 0.001
  276. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood. 2001 Jan 01; 97(1):256-63.
    View in: PubMed
    Score: 0.001
  277. Predictors of survival after In vivo split liver transplantation: analysis of 110 consecutive patients. Ann Surg. 2000 Sep; 232(3):312-23.
    View in: PubMed
    Score: 0.001
  278. Variations in the low levels of cyclin D1/BCL1 have prognostic value in chronic lymphocytic leukemia. Leuk Res. 2000 Jun; 24(6):469-74.
    View in: PubMed
    Score: 0.001
  279. Prediction of prognosis following fludarabine used as secondary therapy for chronic lymphocytic leukemia. Leuk Lymphoma. 2000 Mar; 37(1-2):71-85.
    View in: PubMed
    Score: 0.001
  280. The loss of expression of transforming growth factor-beta receptors correlates with the histopathologic tumor grade in bladder transitional cell carcinoma patients. Yonsei Med J. 1999 Apr; 40(2):118-23.
    View in: PubMed
    Score: 0.001
  281. Level of retinoblastoma protein expression correlates with p16 (MTS-1/INK4A/CDKN2) status in bladder cancer. Oncogene. 1999 Feb 04; 18(5):1197-203.
    View in: PubMed
    Score: 0.001
  282. Deficiency of the ATM protein expression defines an aggressive subgroup of B-cell chronic lymphocytic leukemia. Cancer Res. 1998 Oct 15; 58(20):4552-7.
    View in: PubMed
    Score: 0.001
  283. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med. 1998 Oct 01; 129(7):559-66.
    View in: PubMed
    Score: 0.001
  284. Retinoids in the chemoprevention of bladder cancer. Curr Opin Oncol. 1998 Sep; 10(5):479-84.
    View in: PubMed
    Score: 0.001
  285. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood. 1998 Aug 15; 92(4):1165-71.
    View in: PubMed
    Score: 0.001
  286. Chronic lymphocytic leukemia in the young patient. Semin Oncol. 1998 Feb; 25(1):107-16.
    View in: PubMed
    Score: 0.001
  287. Fludarabine and granulocyte colony-stimulating factor (G-CSF) in patients with chronic lymphocytic leukemia. Leukemia. 1997 Oct; 11(10):1631-5.
    View in: PubMed
    Score: 0.001
  288. Role of splenectomy in chronic lymphocytic leukemia. J Am Coll Surg. 1997 Sep; 185(3):237-43.
    View in: PubMed
    Score: 0.001
  289. Allogeneic blood or marrow transplantation for chronic lymphocytic leukaemia: timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease. Br J Haematol. 1997 May; 97(2):466-73.
    View in: PubMed
    Score: 0.001
  290. Clinical experience with fludarabine in hemato-oncology. Hematol Cell Ther. 1996 Dec; 38 Suppl 2:S83-91.
    View in: PubMed
    Score: 0.001
  291. Bropirimine immunotherapy of upper urinary tract carcinoma in situ. Urology. 1996 Jul; 48(1):28-32.
    View in: PubMed
    Score: 0.001
  292. A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia. Leukemia. 1995 Sep; 9(9):1444-9.
    View in: PubMed
    Score: 0.001
  293. Postradical orchiectomy hemorrhage: should an alteration in staging strategy for testicular cancer be considered? Urology. 1995 Sep; 46(3):408-11.
    View in: PubMed
    Score: 0.001
  294. Interferon maintenance therapy for patients with chronic lymphocytic leukemia in remission after fludarabine therapy. Blood. 1995 Aug 15; 86(4):1298-300.
    View in: PubMed
    Score: 0.001
  295. Fludarabine plus doxorubicin in previously treated chronic lymphocytic leukemia. Leukemia. 1995 Jun; 9(6):943-5.
    View in: PubMed
    Score: 0.001
  296. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res. 1994 Feb 01; 54(3):784-8.
    View in: PubMed
    Score: 0.001
  297. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood. 1993 Sep 15; 82(6):1695-700.
    View in: PubMed
    Score: 0.001
  298. Role of chromosome 9 in human bladder cancer. Cancer Res. 1993 Sep 01; 53(17):4066-70.
    View in: PubMed
    Score: 0.001
  299. Phase II clinical trial of fludarabine in chronic lymphocytic leukemia on a weekly low-dose schedule. Leuk Lymphoma. 1993 Jun; 10(3):187-93.
    View in: PubMed
    Score: 0.001
  300. L-asparaginase and PEG asparaginase--past, present, and future. Leuk Lymphoma. 1993; 10 Suppl:153-7.
    View in: PubMed
    Score: 0.001
  301. Treatment of staghorn calculi with extracorporeal shock-wave lithotripsy and percutaneous nephrolithotomy. Urology. 1991 Aug; 38(2):145-51.
    View in: PubMed
    Score: 0.000
  302. The role of transrectal ultrasonography in the diagnosis and management of prostatic and seminal vesicle cysts. J Urol. 1989 May; 141(5):1206-9.
    View in: PubMed
    Score: 0.000
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.